Curonix

Curonix operates in medical devices and neuromodulation, with a focused position in chronic-pain treatment rather than a broad hospital-device portfolio. Its product scope covers both peripheral nerve stimulation and spinal cord stimulation, while supporting services extend into clinician education, reimbursement assistance, patient navigation, and physician discovery. The company’s differentiation is tied to the Freedom® platform’s minimally invasive, battery-free architecture, its full-body peripheral nerve stimulation positioning, and the addition of NervPulse™ programming capabilities. The October 2025 clinical-trial results and expanded FDA 510(k) indication for chronic craniofacial pain provide evidence of an effort to broaden the addressable use cases for PNS. The January 2026 U.S. launch for craniofacial pain further shifted Curonix from a product portfolio centered on established indications toward a wider nerve-specific pain-management platform. Its formal compliance program and reimbursement resources also address adoption barriers that often sit outside the core device technology.

Curonix’s trajectory shows expansion through product breadth, clinical validation, and organizational strengthening, but not through disclosed financing. Founded in 2010, the company has developed a portfolio around Freedom® peripheral nerve stimulation and spinal cord stimulation systems, supported by education and reimbursement services. The clearest product inflection point came on Mar 27, 2025 with NervPulse™, which added an advanced programming layer to the Freedom PNS System. The Sep 18, 2025 launch of a wearable accessory extended treatment options across the head, neck, shoulder, and upper torso. Clinical publication on Oct 2, 2025 and commercial availability for craniofacial pain on Jan 16, 2026 indicate progression from evidence generation to expanded market access. Curonix also added CFO Russell Fleeger in November 2025 and board member Carlos A. Migoya in August 2026, suggesting increased emphasis on financial management, governance, and strategic expansion. Hiring activity in regulatory affairs, orthopedics product management, and marketing operations is consistent with commercialization and compliance needs.